Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting  by Emmerich, Christoph H. & Cohen, Philip
lable at ScienceDirect
Biochemical and Biophysical Research Communications 466 (2015) 1e14Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcMini reviewOptimising methods for the preservation, capture and identiﬁcation of
ubiquitin chains and ubiquitylated proteins by immunoblotting
Christoph H. Emmerich*, Philip Cohen
Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, University of Dundee, Dundee DD1 5EH, Scotland,
United Kingdoma r t i c l e i n f o
Article history:
Received 11 August 2015
Accepted 24 August 2015






Ubiquitin chain topologyAbbreviations: DMP, dimethyl pimelidinate; DUB
thione S-transferase; HEK, human embryonic kidney;
1 receptor; IMAC, immobilised metal ion afﬁnity ch
precipitation; IRAK, interleukin receptor associated kin
Assembly Complex; MES, 2-(N-morpholino) ethane
morpholino) propane sulfonic acid; NC, nitrocellulo
NEMO, NF-kB essential modulator; NZF, Npl4 zinc ﬁn
PPase, phage l-phosphatase; pUb, polyubiquitin; PV
receptor interacting protein; SDS, sodium dodecyl s
tris-glycine; TNF, tumour necrosis factor; TNF-R, TN
repeated ubiquitin-binding entities; UBA, ubiquitin-
binding in ABIN and NEMO domain; UBD, ubiquitin-
uitin-interacting motif.
* Corresponding author.
E-mail address: c.emmerich@dundee.ac.uk (C.H. E
http://dx.doi.org/10.1016/j.bbrc.2015.08.109
0006-291X/© 2015 The Authors. Published by Elseviera b s t r a c t
Immunoblotting is a powerful technique for the semi-quantitative analysis of ubiquitylation events, and
remains the most commonly used method to study this process due to its high speciﬁcity, speed,
sensitivity and relatively low cost. However, the ubiquitylation of proteins is complex and, when the
analysis is performed in an inappropriate manner, it can lead to the misinterpretation of results and to
erroneous conclusions being reached. Here we discuss the advantages and disadvantages of the methods
currently in use to analyse ubiquitin chains and protein ubiquitylation, and describe the procedures that
we have found to be most useful for optimising the quality and reliability of the data that we have
generated. We also highlight commonly encountered problems and the pitfalls inherent in some of these
methods. Finally, we introduce a set of recommendations to help researchers obtain high quality data,
especially those new to the ﬁeld of ubiquitin signalling. The speciﬁc topics addressed in this article
include sample preparation, the separation, detection and identiﬁcation of particular ubiquitin chains by
immunoblotting, and the analysis of ubiquitin chain topology through the combined use of ubiquitin-
binding proteins and ubiquitin linkage-speciﬁc deubiquitylases.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The discovery of ubiquitin-mediated proteolysis [1] was one of
the most seminal papers published in Biochemical and Biophysical
Research Communications (BBRC), which won Aaron Ciechanover
and Avram Herschko the Nobel Prize for Chemistry 26 years later.
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Inc. This is an open access article ucellular processes and, to date, eight different types of ubiquitin
chain linkage have been identiﬁed in cells [2,3]. These linkages are
formed by the covalent attachment of the C-terminus of ubiquitin
to the ε-amino groups of any of the seven lysine (K) residues in
ubiquitin (K6, K11, K27, K29, K33, K48 and K63) or the a-amino
group of its N-terminal methionine (M1) residue. In addition, some
proteins become mono-ubiquitylated or multi-monoubiquitylated,
in which the ﬁrst ubiquitin attached to a protein does not undergo
polyubiquitylation. Finally, hybrid (also called branched or mixed)
ubiquitin chains containingmore than one type of ubiquitin linkage
have also been identiﬁed in cells [4e6], introducing further
complexity into the system (Fig. 1). Protein ubiquitylation is a
versatile and reversible protein modiﬁcation with regulatory roles
that extend far beyond the proteasome-dependent degradation of
substrate proteins, and include cellular signalling and trafﬁcking, as
well as the control of the cell division cycle and DNA repair.
In recent years there has been an explosion of interest in
ubiquitylation and the number of publications in this area is
increasing exponentially (Fig. S1). It is self evident that the exper-
iments aimed at enhancing our understanding of this process are
conducted to the highest standards of quality control. However, to
our knowledge, no simple, clear guidelines or standardisednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Different types of ubiquitylation. Ubiquitin modiﬁcations can be classiﬁed into three general types, termed monoubiquitylation, multi-monoubiquitylation and poly-
ubiquitylation. Polyubiquitylation can be further subdivided into homotypic ubiquitylation (each ubiquitin chain comprising just one type of ubiquitin linkage) or heterotypic
ubiquitylation (containing more than one type of ubiquitin chain). The latter are usually termed hybrid, branched or mixed ubiquitin chains.
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ubiquitylation events by immunoblotting are available. In this
article, we therefore introduce a number of recommendations
about how to optimise the quality of the information that can be
obtained from such experiments, based on our own experiences
and other published papers in the literature.
2. Preserving the ubiquitylation state of proteins
2.1. Inhibition of deubiquitylases
Protein ubiquitylation is reversible and this modiﬁcation can
therefore easily be lost through the hydrolysis of ubiquitin chain
linkages, which is catalysed by protein ubiquitin hydrolases,
termed deubiquitylases (DUBs). For this reason it is essential to
include DUB inhibitors in the buffers used for cell lysis, to preserve
proteins in the state of ubiquitylation at which theywere present in
the intact cell. The inclusion of DUB inhibitors is particularly critical
during immunoprecipitation (IP) or other “pull-down” experi-
ments, where cell extracts may be incubated for several hours in
non-denaturing conditions. There are ﬁve different families of
DUBs, one of which encodes metallo-proteinases, the other four
being cysteine proteinases. Therefore, to block DUB activity, EDTA
or EGTA must be included in the lysis buffer to remove traces of
heavy metal ions, and Iodoacetamide (IAA) or N-ethylmaleimide
(NEM) must also be added to alkylate the active site cysteine resi-
dues of DUBs. Although IAA or NEM have typically been included at
concentrations of 5e10 mM in many publications, we ﬁnd that up
to 10-fold higher concentrations are needed to preserve the ubiq-
uitylation status of some proteins (e.g. Interleukin receptor asso-
ciated kinase-1 (IRAK1) (Fig. 2A) and ubiquitin chains (Fig. 2B).
High concentrations of NEM are better at preserving K63-Ub chains
andM1-Ub chains than high concentrations of IAA, probably due to
the instability of the latter compound.
An advantage of IAA over NEM is that it is destroyed by light
within minutes, preventing the continued alkylation of cysteine
residues on many proteins. However, the covalent 2-
acetamidoacetamide adduct (C4H6N2O2) formed by the reaction of
IAAwith cysteine residues has amolecular mass of 114 Da [7], which
is identical to that of the GlyeGly dipeptide that remains attached to
the ε-amino group of lysine residues of proteins after ubiquitylated
proteins have been digested with trypsin. This modiﬁcation may
therefore interfere with the identiﬁcation of ubiquitylation sites by
mass spectrometry. It is therefore recommended to use NEM instead
of IAA when such mass spectrometry experiments are to be per-
formed. NEMand IAA are equally compatible for experimentswhere
immunoblotting is the ﬁnal readout.If the ubiquitylation of proteins is to be studied in cell extracts
only, then DUBs can be inactivated by extracting the cells directly
into boiling lysis buffer containing 1% sodium dodecyl sulphate
(SDS). Ubiquitin with a C-terminal cysteine-reactive probe is re-
ported to inactivate some DUBs [8] and, provided that this com-
pound inhibits every DUB, it may also be useful for preventing
deubiquitylation after cell lysis. Other broad-spectrum chemical
inhibitors of DUBs may be identiﬁed in the future.
2.2. Proteasome inhibition
Proteins modiﬁed by all types of ubiquitin linkage, except for
K63-linked and M1-linked chains, can be targeted to the 26S
Proteasome for rapid degradation. For example, in yeast, proteins
modiﬁed by K6-, K11-, K27-, K29- and K33-linked polyubiquitin
(pUb) chains, as well as by K48-linked ubiquitin chains, accu-
mulated in cells when the proteasome was inhibited [9]. Many
inhibitors of the chymotryptic like protease of the proteasome
have been described [10], of which the most widely used is Z-
leucyl-leucyl-leucyl-CHO, termed MG132. Treatment with
MG132 blocks protein degradation and preserves the ubiquity-
lated form of the protein of interest (POI), thereby facilitating its
detection. As an example, pUb-IkBa was only detectable by
immunoblotting if the cells were incubated with MG132 prior to
cell lysis and enriched from the cell extracts using immobilised
Halo-TUBEs (Tandem-repeated Ubiquitin-Binding Entities)
(Fig. 2B, left panel), which capture every type of ubiquitin chain
(Section 5). However, prolonged (12e24 h) treatment with
MG132 can have cytotoxic effects [11] and ubiquitylation
observed after these long incubations might be a consequence of
one or more stress responses.
3. Resolution and identiﬁcation of ubiquitin chains and
ubiquitylated proteins by SDS-PAGE
3.1. Choice of gel and running buffer
Different gels and running buffers for resolving ubiquitylated
proteins by SDS-PAGE are available. Proteins can be modiﬁed by 20
or more ubiquitin molecules that can add >200 kDa to their mo-
lecular mass, resulting in a smear of pUb chains that typically
stretch upwards towards the top of the gel, so that selection of the
most appropriate separation system is important (see Section 10).
The action of E1, E2 and E3 ligases can generate pUb chains in vitro
that differ greatly in length (Fig. 3A). When using pre-poured
gradient gels, a MES (2-(N-morpholino) ethane sulfonic acid)
buffer gives improved resolution of relatively small ubiquitin
Fig. 2. Importance of composition of lysis buffer to prevent deubiquitylation. (A) High concentrations of IAA are required to inactivate deubiquitylases and maintain the level of pUb
chains in cell lysates. Human embryonic kidney (HEK) 293 cells stably expressing the IL-1 receptor (IL-1R cells) were stimulated for 15 min with 5 ng/ml IL-1b and lysed without or
with the indicated concentrations of IAA. Cell lysates were incubated for 12 h with immobilised Halo-NEMO and the ubiquitylated forms of IRAK1 captured were identiﬁed by
immunoblotting. Antibodies against IKKb, which interacts with NEMO in a ubiquitin-independent manner, were used as a loading control. (B) As in A, except that IL-1R cells were
lysed without or with 10 or 100 mM IAA or NEM, respectively. Ubiquitin chains were visualised by immunoblotting with antibodies that recognise K63-pUb or M1-pUb chains. (C)
The proteasomal inhibitor MG132 can preserve the ubiquitylated forms of some POIs. IL-1R cells were incubated for 1 h without (control) or with 25 mMMG132 and then stimulated
with 5 ng/ml IL-1b for the times indicated. Ubiquitylated IkBa captured from cell lysates using immobilised Halo-TUBEs was identiﬁed by immunoblotting (left hand panel). Cell
extracts (20 mg protein) were also immunoblotted for IkBa (right hand panel). It should be noted that IL-1 induces the phosphorylation of IkBa (pIkBa), which leads to its K48-linked
ubiquitylation and proteasomal destruction.
C.H. Emmerich, P. Cohen / Biochemical and Biophysical Research Communications 466 (2015) 1e14 3oligomers comprising 2e5 ubiquitins, whereas a MOPS (3-(N-
morpholino) propane sulfonic acid) buffer gives improved resolu-
tion of pUb chains containing eight or more ubiquitins (Fig. 3A). On
the other hand, a Tris-acetate (TA) buffer is superior for the reso-
lution of proteins in the molecular mass range of 40e400 kDa
(Fig. 3A). When using gels of a single acrylamide concentration of
around 8% and a Tris-glycine (TG) buffer, it is still possible to
separate individual ubiquitin chains comprising up to 20 ubiquitins
(Fig. 3A). However, to be able to detect mono-ubiquitin and short
ubiquitin oligomers, the acrylamide concentration has to be
increased to around 12% (Fig. 3A), at the expense of reducing the
resolution/separation of longer pUb chains.
3.2. Transfer from gels to membranes
To achieve complete transfer of the high molecular mass pUb
chains separated by SDS-PAGE, we recommend electrophoretic
transfer for 2.5 h at 30 V (see Supplementary Information for
technical details). Faster transfer at higher voltages might prevent
ubiquitin chains from re-folding correctly on the membrane, which
can result in non-speciﬁc linkage recognition by pUb chain-speciﬁc
antibodies [12]. Nitrocellulose (NC) and polyvinyl diﬂuoride (PVDF)membranes have been widely used for the detection of ubiquitin
chains. However, until now, no detailed comparison has been made
between the two systems. In Fig. 3B, samples containing either
longer or shorterM1-linked ubiquitin chains of deﬁned length, were
transferred to either PVDF (Millipore; pore size: 0.45 mm; capacity:
294 IgG/cm2) or nitrocellulose (Amersham/GE Healthcare; pore
size: 0.45 mm; capacity: 115e125 IgG/cm2) membranes under
identical conditions (see Supplementary Information for technical
details) and immunoblotted in parallel with an anti-ubiquitin anti-
body. The speciﬁc signal intensity for ubiquitin was higher when
PVDF membranes were used. Both, PVDF and nitrocellulose mem-
brane systems, are also available with a pore size of 0.2 mm, which
can be beneﬁcial when analysing short ubiquitin chains [12].
4. Detection of ubiquitin and ubiquitin chains by
immunoblotting
4.1. Enhancing the performance of anti-ubiquitin antibodies
Ubiquitin is a small globular protein that is difﬁcult to denature
and the ubiquitin epitopes might not be accessible to antibodies due
to insufﬁcient denaturation during SDS-PAGE. Conversely, if an anti-
Fig. 3. Importance of the buffer composition, polyacrylamide gel electrophoresis system and transfer conditions to optimise the detection of ubiquitin chains by immunoblotting.
(A) The Linear UBiquitin Assembly Complex (LUBAC) was immunoprecipitated from cell extracts with antibodies raised against the catalytic component HOIP and incubated with
UBE1, UBE2L3, ubiquitin and MgATP to generate M1-Ub chains, which were then separated using pre-cast NuPAGE Novex (4e12% acrylamide gradient) Bis-Tris gels with either MES-
SDS or MOPS-SDS Running Buffer; or with pre-cast NuPAGE Novex (3e8% acrylamide gradient) Tris-Acetate (TA) gels and TA Running Buffer or 8% and 12% acrylamide gels prepared
in our laboratory with a Tris-Glycine (TG) buffer. (B) M1-pUb chains present in the extracts of IL-1 stimulated IL-1R cells were captured on Halo-NEMO beads and subjected to SDS-
PAGE and transferred either to a PVDF or a nitrocellulose (NC) membrane. M1-pUb chains (2e7 ubiquitin units, 25 ng) were included as a control. In A and B, immunoblotting was
carried out with an anti-ubiquitin antibody (Dako). The numbers on the right hand side of each ﬁgure indicate the number of ubiquitin oligomers in each protein band.
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to recognise its epitope in native ubiquitin. Therefore, after transfer
to PVDF or nitrocellulose membranes, the signal strength of anti-
ubiquitin antibodies can frequently be enhanced signiﬁcantly if
the membrane is subjected to a denaturing treatment prior to
blocking the primary antibody. Any one of the following methods
can be used: 1. Incubation for 15e30 min in boiling water; 2. Incu-
bation for 30 min at 4 C in 20 mM Tris/HCl, pH 7.5, 5 mM 2-
mercaptoethanol containing 6MGuanidine/HCl; 3. Autoclaving [13].
4.2. Choosing the correct ubiquitin antibody
Many monoclonal or polyclonal antibodies that recognise
ubiquitin are available commercially. Most of these bind bothmono-ubiquitin and pUb chains attached covalently to substrate
proteins, but antibodies that only recognise pUb chains and do not
recognise monoubiquitin or mono-ubiquitylated proteins have also
been developed [14]. What is not well known is that different anti-
ubiquitin antibodies do not have equal afﬁnities for all ubiquitin
linkage types. For example, the anti-Ub antibody from Dako does
not recognise M1-pUb oligomers as well as K48- and K63-pUb
chains, the FK1 antibody binds preferentially to K48-linked oligo-
mers and the FK2 antibody binds preferentially to M1-pUb oligo-
mers compared to K48-Ub or K63-Ub oligomers (Fig. 4A).
Interestingly, the anti-Ub antibody from Cell Signalling Technology
barely recognises M1-Ub oligomers (Fig. 4A, right hand panel).
Therefore, the selection of which anti-ubiquitin antibody to use can
be critical.
Fig. 4. Importance of selecting the correct anti-ubiquitin antibody. (A) 25 ng of K48-linked (K482-7), K63-linked (K632-7) or M1-linked (M12-7) ubiquitin oligomers were separated
by SDS-PAGE and visualised by immunoblotting with the different anti-ubiquitin antibodies indicated (the Coomassie-Blue stained gel is shown as a loading control). (B) As in A,
except that K48-, K63- and M1-linked ubiquitin chains were detected with ubiquitin chain-speciﬁc antibodies. For comparison, Coomassie-stained K48-, K63- and M1-linked
trimers and tetramers were labelled.
Table 1
Speciﬁcity of UBDs used to capture pUb chains and pUb-proteins.
Protein/Peptide UBD Speciﬁcity Reference
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antibodies or by their electrophoretic mobility
At the time of writing, pUb chain-speciﬁc antibodies for four
different chain types (K11-, K48-, K63- and M1-linked ubiquitin
chains) are available commercially (e.g. Fig. 4B). The methods used
to make these antibodies have been reviewed [15e17]. Although
chemically identical, the electrophoretic mobility of small ubiquitin
oligomers varies with linkage type. A simple and elegantmethod for
distinguishing between different ubiquitin chain types is therefore
to compare their relative rates of migration after SDS-PAGE (Fig. 4B)
[5,18]. Theway inwhich this has been used to reveal the presence of
hybrid ubiquitin chains is described in Section 6.2.NEMO UBAN domain M1 > K63 chains [21e23]
NEMO [D311N] UBAN domain No Ub-binding [21,24,25]
TAB2 NZF domain K63 chains [26]
TAB2 [T674A/F675A] NZF domain No Ub-binding [27]
Ubiquilin-1 UBA domain All Ub chains [28]
MultiDsk UBA domain All Ub chains [29]
RAP80 dual UIM domains K63 chains [30]
TRABID NZF domain K29 and K33 chains [5]5. Capturing pUb chains and ubiquitylated proteins on
immobilised ubiquitin-binding domains
An unambiguous way to demonstrate the covalent attachment
of pUb chains to proteins is to capture the ubiquitylated form of the
POI from cell extracts using immobilised ubiquitin-bindingdomains (UBDs) of deﬁned ubiquitin chain speciﬁcity (Table 1)
followed by immunoblottingwith antibodies raised against the POI.
A variety of ubiquitin receptors exist, which contain one or several
UBDs that interact with mono-ubiquitin or different types of pUb
chains. More than 20 different families of UBDs have been
described so far [19,20].
When immobilised on a solid support, UBDs can be exploited
to capture and so enrich pUb chains of different linkage types
(Fig. 5A and Table 1) and proteins to which they are attached
Fig. 5. Characterisation of the Halo-UBD pull-down system. (A, B) IL-1R cells were stimulated for the times indicated with 5 ng/ml IL-1b, lysed and the pUb chains captured from the
cell extracts using immobilised Halo-TUBEs or Halo-NEMO. The pUb chains released with SDS were subjected to SDS-PAGE and immunoblotted with the indicated ubiquitin chain-
speciﬁc antibodies (A), or an IRAK1 antibody (B) after incubation of the Halo-TUBEs with l-PPase in the absence (control) or presence of USP2 (B). (C) As in (B), except that RIP1 was
captured from TNF-stimulated THP-1 cells (10 ng/ml for 10 min). Anti-RIP1 was used for immunoblotting. (D) As in A, except that M1-linked-pUb chains were captured using
immobilised Halo-NEMO. The ubiquitin-binding-defective mutant Halo-NEMO[D311N] was included as a control. IKKb, which interacts with NEMO in a ubiquitin-independent
manner, was used as a loading control. (E) pUb chains and pUb-proteins were captured from 3 mg of cell extract protein using the indicated amounts of Halo-NEMO beads
(Lanes 2e6) or Halo-beads (Lane 1), then released from the beads in SDS and identiﬁed by immunoblotting with antibodies against M1-pUb chains or IRAK1. In lanes 8e13, the
supernatants from the pull-downs in lanes 1e6 were incubated with fresh Halo-NEMO beads and captured proteins were examined as before. Nearly all the M1-pUb chains and
pUb-IRAK1 were removed from the cell extracts during the initial incubation, provided that 35 ml of Halo-NEMO beads were used (Lanes 5/6 and 8/9). (F) As in (C), except that
THP-1 cells were stimulated for 15 min with 10 ng/ml TNF and RIP1 was captured from the cell extracts with Halo-NEMO. Cell extracts (20 mg protein) were subjected to SDS-PAGE.
RIP1 was visualised by immunoblotting with an anti-RIP1 antibody.
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Box 1. Capturing pUb chains by using UBDs.
Advantages:
 UBD pull-down assays permit the simultaneous isolation
of the ubiquitylated forms of many endogenous proteins
from cell extracts without any need to overexpress
ubiquitin.
 Linking multiple UBDs together provides an opportunity
to increase avidity and affinity for poly-ubiquitin chains.
Different systems, in particular the MultiDsk or TUBEs
constructs, are now available commercially and well-
characterised [28,29].
 Tag-systems based on the covalent coupling between a
protein fusion tag and synthetic chemical ligands
attached to a solid support (e.g. the HaloTag system)
allow for stringent and extensive washing after the pull-
down and minimise non-specific binding.
 An important benefit of the pull-down method is the
absence of antibody heavy and light chains, which can
otherwise interfere with analysis by immunoblotting.
 Recombinant TUBEs or MultiDsks have also been shown
to protect pUb chains and ubiquitylated proteins in cell
extracts from hydrolysis by a variety of DUBs [28,29]. This
is another way to circumvent the need for chemical inhi-
bition of DUBs after cell lysis to prevent deubiquitylation
(see Section 2.1).
 Ubiquitin-binding-defective mutants can be included as
controls. These mutants (Table 2 and Fig. 6A) enable
proteins that interact with the UBD in a ubiquitin-
dependent manner to be identified very easily and
distinguished from those that bind in an ubiquitin-
independent manner.
Points to consider:
 Glutathione S-transferase (GST) forms dimers and the
dimeric GST moiety of GST-fusion protein can bring
together two UBA (ubiquitin-associated) domains in a
configuration that have been reported to alter their link-
age selectivity [34]. The length of the ubiquitin chains and
their affinity for the UBD may also be modified by GST
dimerization. For these reasons it is recommended that
GST-tagged UBDs are not used for studies of this type.
 Although some UBDs have >100 fold higher affinity for
some Ub chain types than others [21,22], the UBD may
still pull downUb-chain types with which it interactsmore
weakly, particularly if they are expressed at high levels.
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attached to the POI are of unknown topology, immobilised UBDs
that can capture all types of ubiquitin chain should be used
initially (Table 1), such as Halo-tagged TUBEs, (Fig. 5A), which
consists of tandem UBA domain repeats of the protein Ubiquilin-1
(Fig. S2). For example, IRAK1 (Fig. 5B) and RIP1 (Receptor Inter-
acting Protein 1) (Fig. 5C) undergo ubiquitylation within minutes
when cells are stimulated with IL-1 and TNF (Tumour Necrosis
Factor), respectively, and the ubiquitylated proteins can be
captured by Halo-TUBEs.
To prove that material migrating more slowly than the POI is
really caused by its ubiquitylation, the captured proteins must be
treated with a non-speciﬁc DUB, such as USP2 [31], to reconvert the
POI to the unmodiﬁed species (Fig. 5B and C). Combined treatment
with a DUB and a phosphatase may be needed to regenerate the
unmodiﬁed protein, since many proteins contain both types of
covalent modiﬁcation. Once the type(s) of pUb chains is (are)
known more selective UBDs or UBD-containing proteins (Table 1)
that discriminate between pUb chains can be used, such as NF-kB
essential modulator (NEMO) (Fig. 5A).
In these experiments, it is important to also employ an immo-
bilised ubiquitin-binding-defective mutant of the UBD, to establish
that the interaction with the ubiquitin chain or ubiquitylated pro-
tein is speciﬁc (Table 1 and Fig. 5D) and to distinguish these pro-
teins from those that bind in an ubiquitin-independent manner.
However, proteins that bind non-covalently to the UBD or UBD-
containing protein in a stimulus- and ubiquitin-independent
manner can be employed as loading controls in these experi-
ments. For instance, IKKa and IKKb form a multi-subunit complex
with NEMO [32] and can be used as controls in NEMO pull-down
experiments (Fig. 5D).
To be sure that speciﬁc ubiquitin chain types have been
completely depleted from the cell extracts, the supernatants from
the ﬁrst pull-down should be subjected to a second pull-down
(Fig. 5E). Such optimisation studies should be performed at the
start of each new project to determine the amount of immobilised
UBD-coupled beads that need to be added to a given amount of cell
extract to completely deplete the pUb-POI and/or pUb chain of
interest.
The UBD pull-down method is particularly powerful for selec-
tively enriching the ubiquitylated forms of proteins that are only
ubiquitylated to a low stoichiometry in cells. For example, the
ubiquitylated form of RIP1 could only be detected after capture on
immobilised NEMO, and was virtually undetectable in cell extracts
(Fig. 5F).
The immobilised UBDs, but not ubiquitin-binding-defective
mutants of the UBD, will also capture proteins that bind non-
covalently to the ubiquitin chains captured by the UBD. These
proteins can be identiﬁed by mass spectrometry followed by
immunoblotting [4].
UBDs can also be used in “FarWestern” blotting experiments to
detect pUb chains on membranes. In this procedure, protein
samples separated by SDS-PAGE are transferred to a membrane
and incubated with the appropriate puriﬁed UBD (normally
coupled to biotin or horse radish peroxidase). A suitable detection
system is then used to identify the bound UBD and hence the pUb
chains with which it interacts [33]. An advantage of this technique
is that it does not normally require sample denaturation in solu-
tion or on membranes (see Section 4.1). In fact, denatured ubiq-
uitin chains and ubiquitylated proteins may not interact with their
cognate UBDs, resulting in failure to identify an interaction. In this
procedure, it is important to use ubiquitin-binding-defective
mutants of UBDs (Table 1) in parallel with wild type UBDs to
exclude ubiquitin-independent interactions with other UBD-
binding partners.6. Use of deubiquitylases to identify ubiquitin chain linkage
type and topology
6.1. Chain-type speciﬁc DUBs
Over the past few years DUBs with characteristic speciﬁcities for
particular chain types have been identiﬁed [31,35]. The exploitation
of these linkage-speciﬁc DUBs provides a simple and powerful way
to identify and distinguish between the different types of pUb
chains that are attached to ubiquitylated POIs. This approach re-
quires that the POI or pUb chains are ﬁrst captured from cell ex-
tracts (see Section 5) prior to the DUB treatment and analysis of the
Table 2
Speciﬁcity of DUBs useful for ubiquitin chain architecture analysis.
DUB Speciﬁcity Reference




USP5 (IsoT) Free pUb chains not attached to any other protein [36]
vOTU All pUb chains except M1, K27 and K29 [31]
Fig. 6. IL-1 induces the formation of K63/M1-pUb hybrid chains. IL-1R cells were stimulated for 10 min with 5 ng/ml IL-1b, lysed (see Supplementary section 1.3) and pUb chains as
well as ubiquitylated proteins were captured from the cell extracts using immobilised Halo-NEMO (see Supplementary Section 1.4). Prior to SDS-PAGE, samples were incubated with
l-PPase (100 Units) in the absence or presence of AMSH-LP, Otulin, AMSH-LP plus Otulin, or USP2 (concentrations indicated). Following SDS-PAGE and transfer to PVDF membranes,
immunoblotting was carried out with antibodies that recognise IRAK1 (panel A), M1-pUb chains (panel B), K63-pUb chains (panel C) or all types of ubiquitin chains (panel D). K63-
pUb (4 ng) and M1-pUb (10 ng) oligomeric markers (Supplementary Section 1.1), which are shown in lanes 4 and 9, were used as standards to identify the small ubiquitin oligomers
generated by treatment with the different DUBs (Section 6.2).
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At present, several DUBs have been identiﬁed that have a suf-
ﬁciently high speciﬁcity for the hydrolysis of just one type of Ub
linkage (Table 2). However, the non-speciﬁc DUB, termed IsoT or
USP5 can be used to identify the proportion of free ubiquitin chains
in a cell extract that are not attached covalently to any other pro-
tein. This is because IsoT can hydrolyse every type of ubiquitin
linkage, but cannot cleave ubiquitin chains that are attached via
their C-terminus to other proteins, termed “anchored” ubiquitin
chains [36,37]. In contrast, USP2 can hydrolyse every type of
ubiquitin chain, whether they are free or anchored (Table 2) and is
therefore useful for reconverting ubiquitylated proteins to their
unmodiﬁed forms (Fig. 5B and C).
Cells contain several Ub-like proteins that can be attached
covalently to proteins by enzymatic reactions similar to those that
attach ubiquitin to proteins. These include SUMO, NEDD8 and
ISG15. Although some DUBs, such as USP2 and IsoT/USP5 have been
reported to interact with both ubiquitin and ISG15 using active-site
directed probes [40], these DUBs failed to cleave ISG15 from
ISGylated proteins when tested experimentally [41]. USP21 is the
only USP so far shown to cleave ISG15 as efﬁciently as ubiquitin
from proteins [42,43]. To date, no DUB has been reported to cleave
SUMO linkages and only the DUB termed UCH-L3 has been shown
to cleave the NEDD8 conjugated to proteins when tested in vitro
[44]. UCH-L3might therefore function as a C-terminal hydrolase for
both NEDD8 and ubiquitin in cells.
NEDD8-speciﬁc proteases, such as SENP8/NEDP1 [45,46] or
SUMO-speciﬁc proteases, such as SENP2 (R. Hay, personal
communication), can however be used to discriminate between
ubiquitylation, NEDDylation and SUMOylation, These proteases
may be valuable for detecting these Ub-like modiﬁcations specif-
ically when they are attached to the POI or their presence in hybrids
containing polySUMO chains attached covalently to ubiquitin
chains [47,48], as discussed in Section 6.2.
6.2. Detection of hybrid ubiquitin chains
Heterotypic pUb chains of complex topology (termed hybrid
chains, Fig. 1) have recently been identiﬁed and serve specialised
signalling functions within the cell [4e6]. Direct evidence for the
formation of K63/M1-pUb hybrids (Fig. 6AeD) came from the
ﬁnding that when the pUb chains formed in response to cell
stimulationwith IL-1 [4] were captured by Halo-NEMO (see Section
5) and then incubated with Otulin to hydrolyse M1-pUb chains
speciﬁcally (Table 1), small K63-pUb oligomers were liberated that
could be detected by immunoblotting (Fig. 6D). In line with this,
Otulin-treatment also reduced the size of the large K63-pUb chains
induced after IL-1 stimulation (Fig. 6C). Conversely, when the same
pUb chains were incubated with AMSH-LP, a DUB that hydrolyses
K63-pUb chains speciﬁcally (Table 1), the size and amount of the
large M1-Ub chains was reduced (Fig. 6B) and small faster-
migrating M1-pUb oligomers were released from K63/M1-pUb
hybrid chains (Fig. 6D). In these experiments the small K63-Ub
and M1-Ub oligomers could be distinguished from one another
and identiﬁed by their characteristic and distinct electrophoretic
mobilities during SDS-PAGE (see Section 4.3). Finally, treatment
with Otulin increased the electrophoretic mobility of poly-
ubiquitylated IRAK1 but the polyubiquitin chains remaining
attached to IRAK1 were much larger than the monoubiquitylated
forms of IRAK1 (Fig. 6A) [4]. This and other evidence indicated that
theM1-pUb chains were attached covalently to pre-formed K63-Ub
chains attached to IRAK1. Analogous results were obtained when
ubiquitylated RIP2 formed upon cell stimulation with muramyl
dipeptide (a component of bacterial peptidoglycans) was treated
with Otulin [49], demonstrating that hybrid chains containing M1-Ub and at least one other ubiquitin chain linkage type are
commonly formed when innate immune signalling networks are
activated [4,49].
The presence of hybrid ubiquitin chains in other cell signalling
networks can be analysed in similar ways. For example, small K29-
linked pUb oligomers were released from the pUb chains captured
by immobilised tandem NZF domains of TRABID (Table 1),
following incubationwith vOTU, a DUB that does not hydrolyse K29
linkages (Table 2). This indicates that K29 linkages are present in
cells as part of hybrid ubiquitin chains consisting of at least two
different linkage types [5].
Hence, a UBD that binds to one type of ubiquitin chain specif-
ically may nevertheless capture other types of ubiquitin linkage
because proteins can be modiﬁed at multiple lysine residues with
different types of ubiquitin chains and/or because a ubiquitin chain
may contain more than one type of linkage. A protein may also be a
component of a multi-protein complex, and the different protein
components of the complex may be modiﬁed by different types of
ubiquitin chains (or may not be ubiquitylated at all). Thus the UBD
pull-down method can reveal a considerable amount of interesting
information about the composition and ubiquitylation of protein
complexes.7. Immunoprecipitation of ubiquitin chains and
ubiquitylated proteins
7.1. Immunoprecipitation of endogenous, ubiquitylated POIs
Instead of capturing ubiquitylated proteins on immobilised
UBDs, the endogenous ubiquitylated proteins can be immunopre-
cipitated from cell extracts using POI-speciﬁc antibodies that have
been coupled to a solid support (e.g. Protein G agarose), followed by
immunoblotting with a different antibody to the POI to see if it is
ubiquitylated. The type of ubiquitin chain attached to the POI can
then be analysed by treatment with deubiquitylases as outline in
Section 6.7.2. Immunoprecipitation of endogenous ubiquitin
The procedure outlined in Section 7.1 can in theory be reversed
and all the ubiquitylated proteins in the cell immunoprecipitated
with anti-ubiquitin, followed by immunoblotting with an antibody
to the POI to see if it is ubiquitylated. However, in practice, due to
the high abundance of ubiquitin in cells (about 85 mM in
HEK293 cells) [50], the amount of anti-ubiquitin antibody required
to quantitatively immunoprecipitate all the ubiquitylated proteins
from cell extracts makes this method impractical.7.3. Use of monoclonal anti-POI antibodies to detect the
ubiquitylated POI
When using monoclonal antibodies against the POI, it is critical
to remember that the antibody epitope might be blocked or
masked by the presence of a ubiquitin chain, preventing the anti-
body from recognising the modiﬁed version of the POI. For
example, a monoclonal IRAK1 antibody (F-4) only recognises the
modiﬁed protein very weakly, in contrast to a polyclonal antibody
against IRAK1 (H-273) (Fig. 7A). To minimise this problem, which
can lead to the erroneous conclusion that a protein has been
degraded and not ubiquitylated, different monoclonal antibodies
raised against different epitopes or polyclonal antibodies should be
tested.
Box 2. Immunoprecipitation of endogenous ubiquitylated
POIs.
Advantages:
 The endogenous POI is immunoprecipitated from the cell
extracts without the need to overexpress exogenous
ubiquitin.
Potential pitfalls:
 The immunoprecipitation of the POI has to be performed
under non-denaturating conditions, i.e. it is not compat-
ible with buffers containing high concentrations of SDS,
urea or guanidinium chloride (see Section 8.1). Thus,
proteins that interact with the POI will be co-
immunoprecipitated. An anti-Ub antibody cannot there-
fore be used in subsequent immunoblotting experiments
to determine the ubiquitylation status of the POI since it
will also detect the ubiquitylation of interacting proteins
and other proteins present as contaminants in the IPs.
 Ubiquitin chains attached to lysine residues within or
near the antibody-binding region may prevent the isola-
tion and capture of some or all forms of the ubiquitylated
POI. These experiments should therefore be conducted
using polyclonal antibodies raised against two different
regions of the POI (see Section 7.3).
 Depending on the size of the POI, the presence of anti-
body heavy and light chains may interfere with the
detection of the POI by immunoblotting. To avoid this
problem, the antibody can first be cross-linked to a solid
support, using agents such as dimethyl pimelidinate
(DMP). However, this procedure may decrease the affinity
of the antibody for its target protein.
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The ubiquitylation state of the POI can also be studied by
immunoprecipitation of a protein with which it interacts. For
example, the interaction of TNF with the TNF receptor 1 (TNF-R1)
induces the formation of a multi-protein complex, which includes
the protein RIP1. The ubiquitylation of RIP1 can therefore be studied
by stimulating cells with FLAF-tagged TNF, followed by immuno-
precipitation of the TNF-R1 signalling complex with anti-FLAG
antibodies and immunoblotting with anti-RIP1 (Fig. S3).8. Overexpression of ubiquitin
8.1. Tagged ubiquitin
In this method, vector-generated ubiquitin, covalently linked to
protein tags like hemagglutinin (HA), c-Myc, hexa-histidine (His6)
or FLAG octapeptide are transfected into the cell of interest, and
become attached to target proteins because they compete with the
endogenous unmodiﬁed ubiquitin. An advantage of this method is
that anti-tag afﬁnity puriﬁcation methods can be used to enrich
ubiquitylated proteins of interest, which can then be identiﬁed by
immunoblotting with antibodies to the POI. Alternatively, the POI
can ﬁrst be immunoprecipitated with a speciﬁc antibody and its
ubiquitylation status analysed by immunoblotting with the anti-
Tag antibodies. However, in these experiment the ubiquitylatedspecies detected with the anti-tag antibody may not be the POI, but
a POI-interacting protein or a contaminant. It is therefore critical to
remove such proteins from the POI prior to immunoprecipitating
with the anti-tag antibody. This is generally achieved by including
SDS in the cell lysis buffer at a ﬁnal concentration of 1%, and
diluting the cell extract to 0.1% SDS before immunoprecipitating the
POI. This procedure disrupts protein complexes held together by
non-covalent forces. The dilution to 0.1% SDS and absence of thiols
in the lysis buffer is critical to prevent the denaturation and inac-
tivation of the immunoprecipitating antibody. However, the effec-
tiveness of the dissociation procedure has to be controlled by
immunoblottingwith antibodies to proteins known to interact with
the POI comparing samples before and after the addition of 1% SDS.
It is also important to check that proteins do not re-associate when
the SDS concentration is diluted to 0.1%. A serious disadvantage of
this method is that the overexpression of tagged ubiquitin may lead
to the ubiquitylation of proteins that are not normally ubiquitylated
in cells. In addition, the presence of any tag attached to the N- or C-
terminus of ubiquitin will prevent the formation of M1-linked
ubiquitin chains [51].
In humans, the identical ubiquitin molecule is encoded by four
different genes (UBC, UBB, UBA52 and UBA80), the products of
which are then processed to release free ubiquitin. A His6-tagged
ubiquitin has been expressed under the endogenous UBC gene [52]
to enable the tagged-ubiquitin to be expressed at physiological
levels and so minimise potential problems associated with the
overexpression of ubiquitin. However, reducing the level of
expression of tagged ubiquitin may result in the endogenous wild-
type ubiquitin being used preferentially for ubiquitin chain assem-
bly. It is therefore recommendedwhen adopting this procedure, that
three of the endogenous genes are silenced at the same time that the
4th is replaced by a modiﬁed gene encoding the tagged ubiquitin
[53,54]. This was ﬁrst achieved using RNAi, but might be donemore
efﬁciently in the future by CRISPR/CAS9 gene editing technology.
Given all the limitations of using tagged ubiquitin, we recom-
mend that the Method described in Section 5 is used instead.
8.2. The overexpression of ubiquitin mutants
In this procedure all but one of the lysine residues in ubiquitin
are mutated to arginine to prevent their ubiquitylation and N- or C-
terminally tagged versions of these mutants are used to study the
formation of one type of ubiquitin chain in different cellular con-
texts. This approach suffers from the same disadvantages discussed
in Section 8.1. In addition, there is no guarantee that any of these
ubiquitin mutants will be recognised by E1, E2 and E3 ligases as
efﬁciently as thewild type endogenous ubiquitin, that they are fully
functional, expressed at the same levels in cells and that the
observed effects are not due to the mutants being folded improp-
erly. Moreover the incorporation of the mutant ubiquitin into pUb
chains may affect their afﬁnities for UBDs and affect the rate at
which they are hydrolysed by DUBs [55e57]. These mutants can be
useful for generating speciﬁc types of ubiquitin linkages in vitro, but
their use in overexpression studies is not recommended.
9. Determination of the stoichiometry of protein
ubiquitylation
9.1. Determining the ratio between unmodiﬁed and ubiquitylated
proteins
To estimate the proportion of ubiquitylated to unmodiﬁed
protein it is usually necessary to immunoprecipitate the POI, fol-
lowed by immunoblotting with an antibody that recognises the POI
speciﬁcally. This ensures the simultaneous detection of unmodiﬁed,
Fig. 7. Blocking of antibody epitopes by ubiquitin chains. (A) The experiment was performed as in Fig. 5B, except that immunoblotting was carried out using two different anti-
IRAK1 antibodies (polyclonal H-273 and monoclonal F-4). (B) As in A, but after stimulation with IL-1b for the times indicated, cell extracts (20 mg protein) were denatured in SDS,
subjected to SDS-PAGE and immunoblotted with the antibodies shown. The antibody against GAPDH was used as a loading control. (C) As in B, except that IRAK1 was immu-
noprecipitated from the cell extracts (1 mg protein) and incubated without (control) or with USP2 plus l-PPase. Samples were subjected to SDS-PAGE and IRAK1 was visualised by
immunoblotting for 5 s (“short”) (upper panel) or 60 s (“long”) (lower panel) with an anti-IRAK1 antibody.
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However, frequently, only a tiny proportion of the POI undergoes
ubiquitylation in cells (e.g. Fig. 5F). Nevertheless, in the case of RIP1,
this low level of ubiquitylation appears to be sufﬁcient to drive the
TNF signalling network [24]. Therefore trace ubiquitylation of
proteins can have important consequences for cell function.
9.2. Apparent disappearance of proteins from cells
The rapid disappearance of proteins from cells in response to an
extracellular signal, is frequently assumed to be caused by ubiq-
uitylation followed by proteasomal degradation. However, non-
degradative poly-ubiquitylation events can convert the unmodi-
ﬁed protein to a great variety of slowly migrating species (seeSection 10), which can sometimes be difﬁcult to detected by
immunoblotting because any one ubiquitylated species is present
at such a low concentration compared to the unmodiﬁed protein
(Fig. 5F). This problem is compounded if the anti-POI antibodies are
unable to recognise the ubiquitylated forms of the protein (Fig. 7A)
and lead to the incorrect inference that the protein has disappeared
from the cell. To determine whether failure to detect a protein by
immunoblotting is caused by its disappearance or by conversion to
many ubiquitylated, phosphorylated and other covalently modiﬁed
forms of the protein, it is necessary to treat the proteinwith a broad
speciﬁcity DUB and a broad-spectrum protein phosphatase to
completely remove these covalent modiﬁcations. In the case of
IRAK1, the “disappearance” of the protein from cell extracts (Fig. 7B,
left panel) could be fully reversedwhen immunoprecipitated IRAK1
Box 3. Overexpression of tagged versions of ubiquitin.
Advantages:
 When His6-tagged ubiquitin is used, ubiquitylated pro-
teins can be isolated byNi2þ IMAC (immobilisedmetal ion
affinity chromatography). This method is compatible with
strong denaturing conditions (e.g. SDS, 8M urea, 6M
guanidinium chloride) that disrupt non-covalent protein
eprotein interactions and inhibit remaining DUB
activities.
 Efficient and sensitive anti-tag antibodies are available
commercially.
Disadvantages:
 Artificially overexpressing tagged versions of ubiquitin
may affect the physiology and bioactivity of the ubiquitin
molecule in ways that cannot be easily assessed, and lead
to the ubiquitylation of proteins that are not normally
ubiquitylated in cells.
 The presence of any tag linked to the N- or C-terminus of
ubiquitin will prevent the formation of M1-linked Ub
chains [51].
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right panel). Thus, earlier studies that had concluded that IRAK1 is
rapidly degraded by the proteasome were erroneous [58].
10. Appearance of pUb chains and polyubiquitylated proteins
in immunoblotting experiments
It will be apparent from reading this article that small ubiquitin
oligomers of a particular chain type appear on SDS-PAGE as discrete
bands, separated by intervals of about 8 kDa, i.e. themolecularmass
of ubiquitin (Figs. 2C and 3C). In theory, when a substrate protein is
modiﬁedwith a homotypic pUb chain it should also be visualised as
a ladder of bands extending upwards from the expected location of
the unmodiﬁed protein in the gel. However, in practice, ubiquity-
lated proteins are normally seen as a “smear” of ubiquitylated
material extending upwards from the POI to the top of the gel,
which can be detected by immunoblotting with antibodies raised
against the protein of interest or against ubiquitin. This smear, as
opposed to a ladder, is caused by heterogeneity of the modiﬁcation,
which could be due to the presence of more than one type of
ubiquitin linkage, a mixture of polyubiquitylation and multi-
monoubiquitylation or a combination of ubiquitylation and other
modiﬁcations such as phosphorylation and sumoylation. The
presence of hybrid pUb chains will also result in a smear at the level
of immunoblotting (Fig. 1A). A major technical challenge for the
future is to ﬁnd a simple immunoblotting method for distinguish-
ing between polyubiquitylation and multi-monoubiquitylation
(Fig. 1A).
11. Summary of recommendations
In the preceding sections we have discussed the advantages and
disadvantages of the procedures for the detection of ubiquitin
chains and ubiquitylated proteins by immunoblotting that are in
current use and how they are best exploited to obtain accurate,
reliable and reproducible data. In this sectionwe brieﬂy summariseour main recommendations.
Recommendation 1 (Section 2.1): Use IAA or NEM in the cell
lysis buffer at the correct concentration needed to completely
prevent deubiquitylation of the POI and/or the polyubiquitin chains
of interest.
Recommendation 2 (Section 2.2): Block the catalytic activity of
the Proteasome by treating cells for 1 h with 25 mM MG132 to
induce the accumulation of the ubiquitylated form of the POI.
Recommendation 3 (Section 3.1): Choose the most appropriate
polyacrylamide gel and buffer system for the separation of pUb
chains and ubiquitylated-POI, depending on the length of the pUb
chains and the size of the unmodiﬁed POI.
Recommendation 4 (Section 3.1): If a gel of a single poly-
acrylamide concentration is used, check that the longest pUb chains
have really entered the separating gel. The stacking gel should
therefore not be removed, but also submitted to transfer to mem-
branes prior to immunoblotting.
Recommendation 5 (Section 3.1): Since ubiquitylation of the
POI can cause it to migrate over a very wide range of molecular
mass, the PVDF or NC membrane should not be cropped prior to
immunoblotting.
Recommendation 6 (Section 3.2): If you are struggling with
signal strength after transferring the gel to NCmembranes, transfer
to PVDF membranes instead, especially for the detection of short
ubiquitin chains.
Recommendation 7 (Section 4.1): Expose membranes to
denaturing conditions to enhance the binding of anti-ubiquitin
antibodies to ubiquitin chains, particularly if the antibody-
binding site is buried within the intact ubiquitin protein and
therefore not exposed after transfer to membranes. This procedure
might not be necessary for every anti-ubiquitin antibody, but
should be tested whenever antibodies are used for the ﬁrst time.
Recommendation 8 (Section 4.2): It is essential to analyse and
validate the performance of ubiquitin antibodies carefully in terms
of pUb chain-type afﬁnity and preference before deciding which
one to use. Insufﬁcient attention has been paid to potential anti-
body bias and preferences in the past and may require re-
examination of a number of published studies. One should not
assume that different batches of antibody obtained from the same
supplier behave identically.
Recommendation 9 (Section 4.3): When using pUb chain-
speciﬁc antibodies, their performance should be checked with
pure ubiquitin oligomers of known linkage type alongside the test
samples. This ensures that speciﬁcity of the antibody is maintained
throughout the experiment (primary antibody dilution, IP condi-
tions, use of PVDF or NC membranes).
Recommendation 10 (Section 5): To detect ubiquitin modiﬁ-
cations of POIs, use immobilised UBDs to capture them, followed by
immunoblotting with anti-POI antibodies.
Recommendation 11 (Section 5): Use non-speciﬁc DUBs, like
USP2, to prove that the observed modiﬁcation is due to the
attachment of ubiquitin chains and not to another type of modiﬁ-
cation, including modiﬁcation by other ubiquitin-like modiﬁers
(Nedd8, SUMO, ISG). Use IsoT to examine whether ubiquitin chains
are “free” or are attached covalently to another protein(s).
Recommendation 12 (Section 5): Use Ubiquitin-binding-
defective mutants of UBDs to establish that the interaction of a
protein with a UBD is ubiquitin-dependent.
Recommendation 13 (Section 5): At the outset of each study,
determine the amount of UBD-coupled beads required to
completely deplete the ubiquitin chains of interest and/or the
ubiquitylated form of the POI from the cell extracts (for further
technical details see the Supplementary Information).
Recommendation 14 (Section 6.1): When using DUBs, their
speciﬁcity should be checked using recombinant ubiquitin
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samples. Although AMSH-LP hydrolyses K63-Ub chains and not
other type of ubiquitin chain, at high concentrations it can also
hydrolyse the isopeptide bond formed between the C-terminus of
ubiquitin and the ε-amino group of a lysine residue in the POI to
which the pUb chain is attached. Samples should therefore be
treated for the minimum length of time and at the lowest possible
concentration of AMSH-LP needed to hydrolyse all the K63-Ub
chains in the sample (see Supplementary Information for further
technical details).
Recommendation 15 (Section 7): As for all immunoprecipita-
tion/immunoblotting studies, the optimal amount and concentra-
tion of the antibodies to use, and the time needed to ensure
efﬁcient immunoprecipitation should be determined at the outset
of the study.
Recommendation 16 (Section 7.1): When the POI has been
immunoprecipitated, do not use anti-ubiquitin antibodies to anal-
yse whether it is ubiquitylated. This is because the anti-ubiquitin
antibodies will also detect ubiquitylation forms of proteins that
interact with the POI or that were immunoprecipitated non-
speciﬁcally by the antibody. Always use anti-POI antibodies
instead as a requirement to establish that the POI is modiﬁed by
ubiquitin chains.
Recommendation 17 (Section 7.3): Remember that some anti-
bodies may only recognise the unmodiﬁed protein and not the
ubiquitylated protein. Different antibodies raised against different
epitopes, or polyclonal antibodies should also be used to circum-
vent this problem.
Recommendation 18 (Section 8): The overexpression of
tagged-versions of wild type andmutant ubiquitins may lead to the
abnormal ubiquitylation of proteins and to erroneous conclusions
being reached, and is not recommended for reasons discussed in
Sections 8.1 and 8.2. However, if such experiments are performed,
the anti-tag antibodies should only be used for immunoprecipita-
tion and anti-POI antibodies should be employed to analyse the
ubiquitylation state of the POI (see Recommendation 16).
Recommendation 19 (Section 9.2): The immunoprecipitated
POI should always be incubated with and without USP2 to hydro-
lyse all the ubiquitin chains, prior to immunoblotting with anti-
bodies to the POI. These experiments enable the proportion of the
POI that is ubiquitylated to be assessed and can be used to deter-
mine whether the POI has been ubiquitylated or degraded.
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